Human immunodeficiency virus remains one of the world’s most pressing health challenges, and a new editorial published in BMC Global and Public Health argues that progress against the epidemic now depends as much on social and structural factors as on biomedical advances. According to the joint United Nations Programme on HIV/AIDS, more than 40 million people worldwide were living with HIV in 2025, and over half a million people died of HIV-related illnesses that year.
The first of these themes concerns people who interrupt or abandon their HIV treatment. The editorial highlights a systematic review by Kwarah and colleagues that examined the validation, development and application of machine learning models designed to predict HIV treatment interruption. The review’s conclusions were described as optimistic but cautious: machine learning may help identify people at risk of disengaging from care, but stronger evidence was required before such models could be considered reliable predictive tools. Since that publication, the editorial notes, supportive evidence has emerged suggesting that machine learning can identify patients likely to stop treatment early and can provide patient-specific risk predictions.
Technology is not the only route to better adherence. The editorial also points to social and economic interventions as a more established option for improving treatment outcomes. A longitudinal observational study by Thapa and colleagues followed HIV patients enrolled in a microfinance programme in western Kenya and compared them with patients who were not members. The study found that participation in the programme was associated with significantly better HIV outcomes, including viral suppression. The editorial describes it as encouraging that both established and emerging interventions are delivering meaningful benefits, and it anticipates further insights as artificial intelligence becomes more widely adopted in HIV care.
The second core theme is inequality, which the editorial stresses is evident throughout the HIV care continuum even in wealthier countries. In the United Kingdom and the United States, socioeconomic disadvantage is associated with poorer HIV outcomes, including lower treatment adherence and lower rates of viral suppression. Consistent with this pattern, a population-based cohort study by Yeong and colleagues in British Columbia, Canada, found significant differences in viral non-suppression across HIV exposure groups. The editorial argues that these findings underscore how inequities in HIV outcomes persist even in well-resourced settings with extensive access to care and treatment.
According to the editorial, addressing such inequalities has value beyond the populations directly affected. The point reflects a broader argument running through the piece: that HIV research must be understood as a global enterprise in which findings from one setting can illuminate problems in another.
The third theme, stigma, is described as a prominent concern within communities of people living with HIV, particularly among vulnerable groups such as adolescents. In these populations, HIV-related stigma has been linked with poor mental health, worse quality of life and reduced treatment adherence. Qualitative research by Faidas and colleagues, studying homogenous populations in the Malawian context, found that HIV-related stigma both contributes to declines in mental health and reduces engagement in HIV care, illustrating the dual role of stigma as both a social problem and a determinant of health.
The editorial extends this argument with work by Mukerji and colleagues, who explored intersectional stigma among women living with HIV in India. That research found that stigma often intersects with violence and marginalised identities, resulting in increased stress and a reluctance to seek help. Taken together, the editorial contends, the variation in the lived experiences of people living with HIV demonstrates to researchers and policy-makers that biomedical interventions alone will not close gaps in HIV outcomes or quality of life. Social, economic, cultural and political factors must also be considered in any serious response to the epidemic.
Looking forward, the editorial strikes a note that is both optimistic and sobering. It acknowledges the noticeable progress in HIV prevention and treatment in recent years and the declining number of new global HIV cases. Yet it also warns that growing populations and longer life expectancies will likely result in more people living with HIV for longer periods of time. Citing a recently commissioned global Perspective published in The Lancet, the editorial stresses that viral suppression is only part of the solution: HIV care must now incorporate healthy-ageing support and address comorbidities, mental health, functional decline and community-based care needs.
The overall message is that research into HIV care has fundamentally improved the lives of people living with the virus, but that existing gaps in care equality and variation in quality of life highlight clear opportunities for public health intervention.
Subject of Research: An editorial on HIV treatment disengagement, care inequalities and stigma among people living with HIV.
Article Title: Understanding HIV risk across populations
Article References: Cranfield, B. (2026). Understanding HIV risk across populations. BMC Global and Public Health, 4(1), Article 91. https://doi.org/10.1186/s44263-026-00328-0
Image Credits: AI Generated
DOI: 10.1186/s44263-026-00328-0
Keywords: HIV, UNAIDS, treatment disengagement, machine learning, microfinance, health inequality, stigma, viral suppression, mental health, global public health, BMC Global and Public Health, people living with HIV
News Source: Phoebe Ingram. (October 30, 2026). HIV research highlights treatment gaps, inequality and stigma worldwide. Scienmag.
